Enanta Pharmaceuticals, Inc. (ENTA)
$
8.69
+0.16 (1.84%)
Key metrics
Financial statements
Free cash flow per share
-3.8570
Market cap
185.8 Million
Price to sales ratio
2.8665
Debt to equity
2.6123
Current ratio
4.9992
Income quality
0.5753
Average inventory
0
ROE
-0.8902
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Enanta Pharmaceuticals, Inc., founded in 1995 and headquartered in Watertown, Massachusetts, focuses on the discovery and development of small molecule drugs aimed at treating viral infections and liver diseases. The company targets various diseases through its research and development efforts, including respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. In its financial operations, the company reported selling, general, and administrative expenses of $57,850,000.00 indicating its operational overhead costs. The operating expenses amount to $189,326,000.00 encompassing various operational costs incurred during the year. Additionally, the company incurred an income tax expense of -$1,743,000.00 reflecting its obligations to tax authorities. Evaluating operational performance, the EBITDA ratio is -1.55 highlighting the company's operational efficiency. Furthermore, the gross profit stands at $67,635,000.00 showcasing the company's profitability from its core operations. Enanta has a collaborative development agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitors, including paritaprevir and glecaprevir for treating chronic hepatitis C virus. In the investment landscape, the stock is affordable at $6.96 making it an appealing option for budget-conscious investors. However, the stock has a low average trading volume of 173,792.00 indicating lower market activity that might attract investors looking for stability. With a market capitalization of $185,769,232.00 the company is classified as a small-cap player, which often appeals to investors seeking growth opportunities within burgeoning enterprises. Enanta Pharmaceuticals, Inc. is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its innovative approaches. Moreover, it belongs to the Healthcare sector, driving innovation and growth as it continues to advance its pipeline of drug candidates.
Is Enanta Pharmaceuticals, Inc. (ENTA) a good investment?
Investing in Enanta Pharmaceuticals, Inc. (ENTA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Enanta Pharmaceuticals, Inc. (ENTA)'s stock forecast?
Analysts predict Enanta Pharmaceuticals, Inc. stock to fluctuate between $4.09 (low) and $13.37 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Enanta Pharmaceuticals, Inc.'s market capitalization?
As of 2025-08-29, Enanta Pharmaceuticals, Inc.'s market cap is $185,769,232, based on 21,377,357 outstanding shares.
How does Enanta Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Enanta Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Enanta Pharmaceuticals, Inc. (ENTA) stock?
To buy Enanta Pharmaceuticals, Inc. (ENTA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENTA. Place an order (Market, Limit, etc.).
What is the best time to invest in Enanta Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Enanta Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $67,635,000 | EPS: -$5.48 | Growth: -14.11%.
Where can I find Enanta Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.enanta.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Enanta Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Enanta Pharmaceuticals, Inc. stock?
All-time high: $102 (2021-11-05) | All-time low: $4.09 (2025-04-09).
What are the key trends affecting Enanta Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
8 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside Chat on Wednesday, September 3, 2025 at 8:35 a.m. ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside Chat on Tuesda.
businesswire.com
9 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '26.
zacks.com
18 days ago
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $1.07 per share a year ago.
businesswire.com
18 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)-- #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2025. “This past quarter we continued to make steady progress across our pipeline, marked by the completion of enrollment in the RSVHR trial, a proof-of-concept study of zelicapavir in high-risk adults infected w.
businesswire.com
24 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. “HCW@Home” series. A live webcast of the event will be accessible by visiting the “Events and Presentations” section.
businesswire.com
a month ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird's Biotech Discovery Series. A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page.
businesswire.com
3 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved as the only eight-week treatment for adults and pediatric patients three.
businesswire.com
3 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the “Even.
businesswire.com
3 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 2.
zacks.com
3 months ago
The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
See all news
